Sofinnova Investments Inc

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Sofinnova Investments Inc
CRD #160297
SEC #801-110134
CIK #0001631134
AUM 5,368.5 M (2026-03-27)
Employees 41 (49% Investors, 0% Brokers)
Fees
Minimum
Phone650-681-8420
Address3000 Sand Hill Road
Menlo Park, CA 94025
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
6.04.83.62.41.20.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/27/2026) [Brochure]
Item 5 – Fees and Compensation

A. and C.

Funds:

    Sofinnova charges each Fund an investment management fee based on the value of the Fund’s assets
    under management, capital commitments or invested capital (collectively, the “Management Fees”).
    The Management Fee rates of the Funds range from 1.25% to 2.50% (per annum). The Management
    Fees are: (i) charged monthly or quarterly in advance; and (ii) prorated for any period that is less than
    a full month or calendar quarter (as applicable). In general, the proration of Management Fees is
    calculated based on the number of days remaining in the applicable period. The Management Fees
    are generally deducted from each Fund account by the Funds’ administrator upon Sofinnova’s
    instructions. For more detailed information and a complete description of the Management Fees paid
    to Sofinnova, please refer to the Fund Documents of the relevant Fund.

    Sofinnova is entitled to receive performance-based compensation from the Funds in the form of
    carried interest distributions or incentive allocations, which is compensation that is based on net
    profits (including net unrealized gains in respect of the Public Clients) attributable to Fund
    investments. This compensation ranges from 20% to 25% of the net profits, subject to a loss
    carryforward or a hurdle carryforward provision in respect of the Public Clients. Further, receipt of
    performance-based compensation is subject to a hurdle in respect of certain Funds. Performance-
    based compensation is allocable to Sofinnova as of the end of each year in respect of certain Funds,
    and upon withdrawals or other distributions with respect to all Funds. Further, Sofinnova may cause
    all or any portion of performance-based compensation to which it would otherwise be entitled to be
    allocated to one or more persons or entities. For more detailed information and a complete

     description of the performance-based compensation allocable to Sofinnova, please refer to the Fund
     Documents of the relevant Fund.

     The Management Fees and performance-based compensation are subject to waiver or reduction by
     Sofinnova in its sole discretion, both voluntarily and on a negotiated basis with selected investors via
     side letter or other similar arrangements. In that regard, certain Fund investors who are current or
     former members, principals, employees or affiliates of Sofinnova, as well as relatives or friends of
     those persons, are generally not subject to Management Fees or performance-based compensation.

     Separate Accounts:

     The Separate Account clients generally pay an annual investment management fee that is negotiated
     on a case by case basis and, in certain cases, are lower than those paid by the Funds. Separate Account
     clients are generally required to pay management fees monthly in arrears. In addition, the Firm is
     entitled to a performance fee pursuant to the terms of each Investment Advisory Agreement. The
     Firm may reduce, waive or calculate differently the fees with respect to any Separate Account client.

B.
     Funds:

     In addition to management fees and performance-based compensation, each Fund generally bears its
     own expenses in accordance with its Fund Documents, including, without limitation, the expenses set
     forth below:

         Venture Funds

              •   Organization costs of the Fund and the General Partners;
              •   All costs and expenses incurred in the purchase, holding, sale, exchange or other
                  disposition of portfolio securities; including taxes applicable to the Fund on account of its
                  operations; fees incurred in connection with the maintenance of bank or custodian
                  accounts; brokerage fees; legal, audit, private placement and finder’s fees paid to persons
                  other than the General Partner or members of the General Partner, and other expenses
                  incurred in connection with the registration of the Fund’s portfolio securities under the
                  Securities Act of 1933 (the “Securities Act”); legal and accounting fees and expenses
                  incurred in connection with the purchase, sale, exchange or other disposition of securities
                  (whether or not such purchase, sale or exchange or other disposition is ultimately
                  consummated); and fees and expenses of investment advisers and independent
                  consultants incurred in investigating and evaluating investment opportunities;
              •   All fees incurred in connection with the annual audit of the Fund and the preparation of
                  the Fund’s annual tax return, costs of independent appraisers, legal expenses of the Fund,
                  premiums associated with insurance, if any; preparation and other expenses associated
                  with annual and other reports to the investors, costs associated with any Fund meetings;
                  legal fees and expenses incurred in prosecuting or defending administrative or legal
                  proceedings relating to the Fund; administration fees and expenses;
              •   Indebtedness of, or guarantees made by, the Partnership, the General Partner, the
                  Management Company or any of their Affiliates on behalf of the Partnership (including

           any credit facility, letter of credit or similar credit support), including interest with respect
           thereto, or seeking to put in place any such indebtedness or guarantee
       •   All liquidation costs, fees, and expenses incurred by the Fund or its General Partner.

   Public Funds

       •   The fees and expenses of the independent directors of the Fund (if applicable);
       •   Fees paid to proxy and securities class action advisory firms;
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/27/2026) [Brochure]
Item 7 – Types of Clients

Sofinnova provides investment advisory services to Funds and the Separate Accounts.

With respect to the Funds, any initial and additional subscription minimums are disclosed in the relevant
Fund Documents. Minimum investment amounts have been, and may in the future be, reduced in
Sofinnova’s sole discretion.

Although Sofinnova does not maintain a specific minimum dollar value of assets or other conditions for
opening a separately managed account, any such additional account relationship would generally involve
a significant minimum account size.
Sector Form 13F Holdings Value ($B)
Natera Inc 0.3
United Therapeutics Corp 0.1
Bristol Myers Squibb Co 0.1
Jazz Pharmaceuticals Inc 0.1
Vera Therapeutics Inc 0.1
Astrazeneca PLC 0.1
UNUM Therapeutics Inc 0.1
Celcuity Inc 0.1
Ultragenyx Pharmaceutical Inc 0.1
Axsome Therapeutics Inc 0.1
View All
Holdings by Sector ($B)
3.02.41.81.20.60.02018202120242027
Type Form D Funds Date Sold AUM
VC Sofinnova Venture Partners XII LP [2025-03-20] 500.0 M 20.5 M
Offered $550,000,000 · Filed 2025-08-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $49,971,939 · Duration One year or less · Commission $1,966,594 · Revenue Not Applicable
HF Sofinnova Bioequities Enhanced Master Fund LP [2023-03-29] 41.5 M 1,194.9 M
Filed 2025-10-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Sofinnova Synergy Master Fund LP [2022-03-30] 4.9 M
Filed 2024-10-02 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
VC Sofinnova Venture Partners Xi LP [2022-03-30] 500.0 M 308.7 M
Offered $500,000,000 · Filed 2023-09-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $2,869,725 · Revenue Not Applicable
HF Sofinnova Bioequities Master Fund Ltd [2017-03-03] 363.7 M 121.4 M
Filed 2025-05-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
VC Sofinnova Venture Partners X LP [2017-03-03] 595.5 M 259.3 M
Offered $650,000,000 · Filed 2016-08-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $54,500,000 · Duration One year or less · Revenue Not Applicable
VC Sofinnova Venture Partners IX LP [2015-03-27] 389.3 M
Offered $500,000,000 · Filed 2014-07-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $500,000,000 · Duration One year or less · Revenue Not Applicable
VC 80 [2014-03-27] 65.3 M 2.2 M
Offered $110,000,000 · Filed 2014-07-07 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $44,650,000 · Duration One year or less · Revenue Not Applicable
VC 194 2012-03-30 0.0 M
VC 294 2012-03-30 0.2 M
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 9 2.9
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 11 2.4
(n) Other 0 0.0
Total 20 5.4
By Discretionary
Discretionary 20 5.4
Non-Discretionary 0 0.0
Total 20 5.4
By Non-United States Persons
Non-United States Persons 3.3
United States Persons 2.1
Total 20 5.4
Limited Partners2011 - 2026
California State Teachers' Retirement System
Massachusetts Pension Reserves Investment Management
Oregon Public Employees Retirement Fund
San Diego County Employees Retirement Association
Teachers' Retirement Security for Illinois Educators
The University of Texas/Texas A&M Investment Company
Form D Directors Role # Filings # Firms 2011 - 2026
James Healy Executive Officer 49 4
Garheng Kong Executive Officer 60 3
David Kabakoff Executive Officer 29 3
Srinivas Akkaraju Executive Officer 28 3
Randy Scott Executive Officer 26 3
Michael Powell Executive Officer 52 2
Anand Mehra Executive Officer 20 2
Maha Katabi Executive Officer 13 2
Sofinnova Investments Inc Executive Officer 3 2
Tom Callaway Executive Officer 2 2
Sarah Bhagat Executive Officer 2 2
Eric Delbridge Executive Officer 2 2
Sofinnova Bioequities GP LLC Executive Officer 2 1
Sofinnova Ventures Inc Executive Officer 1 1
General Partner Sofinnova Synergy Fund GP LLC Promoter 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001631134]
SC 13G [0001631134]
Form 13D/13G Filer Form 13D/13G Subject Filed
Sofinnova Investments Inc Marinus Pharmaceuticals Inc [2024-11-14]
Sofinnova Investments Inc Otonomy Inc [2021-02-16]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI549300HVTF5RFS1C0D72
Comparable Firms State AUM
Vestal Point Capital LP
NY 5,469.1 M
Palestra Capital Management LLC
NY 5,441.9 M
STWD Investment Management LLC
FL 5,434.0 M
Aquatic Capital Management LLC
IL 5,430.4 M
Stockbridge Partners LLC
MA 5,411.2 M
Blackstone Alternative Investment Advisors LLC
NY 5,391.0 M
Silver Rock Financial LP
CA 5,381.0 M
Ashoka Whiteoak Capital PTE Ltd
5,378.8 M
Mantle Ridge LP
NY 5,348.8 M
Polus Capital Management Limited
5,319.4 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com